Tricyclic heterocycles as BET protein inhibitors

1. A method of treating BET-mediated cancer, wherein the cancer is leukemia, lymphoma, multiple myeloma, brain cancer, neuroblastoma, carcinoma, skin cancer, lung cancer, or prostate cancer, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

represents a double bond;

L is O;

Cy 1 is selected from phenyl or a 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said phenyl or 5-6 membered heteroaryl of Cy 1 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R 11 ;

R 1 and R 2 are independently selected from H, halo, CN, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, OR a1 , SR a1 , C(═O)R b1 , C(═O)NR c1 R d1 , C(═)OR a1 , OC(═O)R b1 , OC(═O)NR c1 R d1 , NR c1 R d1 , NR c1 C(═O)R b1 , NR c1 C(═O)NR c1 R d1 , NR c1 C(═O)OR a1 , S(═O)R b1 , S(═O)NR c1 R d1 , S(═O) 2 R b1 , NR c1 S(═O) 2 R b1 and S(═O) 2 NR c1 R d1 , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R 1 and R 2 are optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR a1 , SR a1 , C(═O)R b1 , C(═O)NR c1 R d1 , C(═)OR a1 , OC(═O)R b1 , OC(═O)NR c1 R d1 , NR c1 R d1 , NR c1 C(═O)R b1 , NR c1 C(═O)NR c1 R d1 , NR c1 C(═O)OR a1 , S(═O)R b1 , S(═O)NR c1 R d1 , S(═O) 2 R b1 , NR c1 S(═O) 2 R b1 and S(═O) 2 NR c1 R d1 ;

provided neither R 1 nor R 2 are Cl, Br, I, CN, or OH;

alternatively, R 1 and R 2 together with the carbon atom to which they are attached are combined to form a C 3-7 cycloalkyl group, wherein said cycloalkyl group is optionally substituted with 1, 2, 3, or 4 groups independently selected from R 20 ;

Cy 3 is selected from phenyl, C 3-7 cycloalkyl, a 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said phenyl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Cy 3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 , wherein a ring-forming nitrogen atom of said 5-10 membered heteroaryl group or a ring-forming nitrogen atom of said 4-10 membered heterocycloalkyl group is optionally oxidized;

R 4 is H, C(═O)NR 14a R 14b , C(═O)R 14a , C(═O)OR 14a , or C 1-6 alkyl optionally substituted by 1, 2, or 3 substituents independently selected from halo, NR 14a R 14b , OR 14a , SR 14a , CN, C(═O)R 14a , C(═O)NR 14a R 14b , C(═O)OR 14a , OC(═O)R 14b , OC(═O)NR 14a R 14b , NR 14a C(═O)R 14b , NR 14a C(═O)NR 14a R 14b , NR 14a C(═O)OR 14b , S(═O)R 14a , S(═O)NR 14a R 14b , S(═O) 2 R 14a , NR 14a S(═O) 2 R 14b , and S(═O) 2 NR 14a R 14b ;

R 5 is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, NR 15a R 15b , —C(═O)NR 15a R 15b , —C(═O)OR 15a , phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C 1-6 alkyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-10 membered heterocycloalkyl of R 5 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R 15 ;

R 6 is absent;

R 7 is selected from H, halo, CN, OR a , NR c R d , SR b , C(═O)NR c R d , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl group, and a 4-7 membered heterocycloalkyl group of R 7 are optionally substituted with 1, 2, or 3 groups independently selected from R 17 ;

R 8 is selected from H, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, halo, CN, OR a , NR c R d , SR b , and C(═O)NR c R d , wherein said C 1-3 alkyl of R 8 is optionally substituted with 1, 2, or 3 groups independently selected from R 18 ;

R 9 and R 9a are independently selected from H, C 1-3 alkyl, C 1-3 haloalkyl, halo, CN, OR a , NR c R d , SR b , and C(═O)NR c R d ;

R 11 is independently at each occurrence selected from H, C 1-3 alkyl, C 1-3 haloalkyl, halo, CN, OR a , NR c R d , SR b , and C(═O)NR c R d , wherein said C 1-3 alkyl is optionally substituted by OH;

R 13 is independently at each occurrence selected from H, halo, CN, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, OR a3 , SR a3 , C(═O)R b3 , C(═O)NR c3 R d3 , C(═O)OR a3 , OC(═O)R b3 , OC(═O)NR c3 R d3 , NR c3 R d3 , NR c3 C(═O)R b3 , NR c3 C(═O)NR c3 R d3 , NR c3 C(═O)OR a3 , S(═O)R b3 , S(═O)NR c3 R d3 , S(═O) 2 R b3 , NR c3 S(═O) 2 R b3 and S(═O) 2 NR c3 R d3 , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R 13 is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR a3 , SR a3 , C(═O)R b3 , C(═O)NR c3 R d3 , C(═O)OR a3 , OC(═O)R b3 , OC(═O)NR c3 R d3 , NR c3 R d3 , NR c3 C(═O)R b3 , NR c3 C(═O)NR c3 R d3 , NR c3 C(═O)OR a3 , S(═O)R b3 , S(═O)NR c3 R d3 , S(═O) 2 R b3 , NR c3 S(═O) 2 R b3 and S(═O) 2 NR c3 R d3 ;

R 15 is independently at each occurrence selected from H, C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, CN, OR a5 , SR a5 , C(═O)R b5 , C(═O)NR c5 R d5 , C(═O)OR a5 , OC(═O)R b5 , OC(═O)NR c5 R d5 , NR c5 R d5 , NR c5 C(═O)R b5 , NR c5 C(═O)NR c5 R d5 , NR c5 C(═O)OR a5 , S(═O)R b5 , S(═O)NR c5 R d5 , S(═O) 2 R b5 , NR c5 S(═O) 2 R b5 , and S(═O) 2 NR c5 R d5 , wherein said C 1-6 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR a5 , SR a5 , C(═O)R b5 , C(═O)NR c5 R d5 , C(═O)OR a5 , OC(═O)R b5 , OC(═O)NR c5 R d5 , NR c5 R d5 , NR c5 C(═O)R b5 , NR c5 C(═O)NR c5 R d5 , NR c5 C(═O)OR a5 , S(═O)R b5 , S(═O)NR c5 R d5 , S(═O) 2 R b5 , NR c5 S(═O) 2 R b5 , S(═O) 2 NR c5 R d5 , 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl, and C 3-7 cycloalkyl;

R 14a and R 14b are independently at each occurrence selected from H and C 1-6 alkyl, wherein said C 1-6 alkyl of R 14a and R 14b is optionally substituted with 1, 2, or 3 substituents selected from R 20 ;

or R 14a and R 14b together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents selected from R 20 ;

R 15a and R 15b are independently at each occurrence selected from H and C 1-6 alkyl, wherein said C 1-6 alkyl of R 15a and R 15b is optionally substituted with 1, 2, or 3 substituents selected from R 20 ;

or R 15a and R 15b together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents selected from R 20 ;

R 17 and R 18 are independently at each occurrence selected from halo, C 1-4 alkyl, CN, OR a , NR c R d , SR b , C(═O)NR c R d , C(═O)OR a , and NR c C(═O)R a ;

R a , R c , and R d are independently at each occurrence selected from H, C 1-6 alkyl, C(O)R c , S(═O) 2 R f , C(═O)NR g R h , and phenyl optionally substituted by C 1-4 alkoxy;

R b is at each occurrence C 1-6 alkyl;

R e is at each occurrence C 1-4 alkyl optionally substituted by a group selected from phenyl, C 1-4 alkoxy, amino, C 1-4 alkylamino, and C 2-8 dialkylamino;

R f is C 1-4 alkyl;

R g and R h are independenetly at each occurrence selected from H and C 1-4 alkyl;

R a1 , R b1 , R c1 and R d1 are independently at each occurrence selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 1-6 haloalkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl forming R a1 , R b1 , R c1 and R d1 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 20 ;

R a3 , R b3 , R c3 and R d3 are independently at each occurrence selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, and C 1-6 haloalkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl forming R a3 , R b3 , R c3 and R d3 are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, OR a4 , SR a4 , C(═O)R b4 , C(═O)NR c4 R d4 , C(═O)OR a4 , OC(═O)R b4 , OC(═O)NR c4 R d4 , NR c4 R d4 , NR c4 C(═O)R b4 , NR c4 C(═O)NR c4 R d4 , NR c4 C(═O)OR a4 , S(═O)R b4 , S(═O)NR c4 R d4 , S(═O) 2 R b4 , NR c4 S(═O) 2 R b4 and S(═O) 2 NR c4 R d4 ;

R a4 , R b4 , R c4 and R d4 are independently at each occurrence selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 1-6 haloalkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl forming R a4 , R b4 , R c4 and R d4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 20 ;

R a5 , R b5 , R c5 and R d5 are independently at each occurrence selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl, and C 1-6 haloalkyl wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl forming R a5 , R b5 , R c5 and R d5 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 20 ;

or R c5 and R d5 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from R 20 ; and

R 20 is at each occurrence independently selected from H, halo, OH, CN, amino, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 alkyl—C(═O)—, C 1-4 alkyl—C(═O)O—, C 1-4 alkyl—OC(═O)—, HOC(═O)—, H 2 NC(═O)—, C 1-4 alkyl—NHC(═O)—, di(C 1-4 alkyl)NC(═O)—, C 1-4 alkyl—C(═O)NH—, C 1-4 alkyl—O—C(═O)NH—, C 1-4 alkyl—S(═O)—, H 2 NS(═O)—, C 1-4 alkyl—NHS(═O)—, di(C 1-4 alkyl)NS(═O)—, C 1-4 alkyl—S(═O) 2 —, C 1-4 alkyl—S(═O) 2 NH—, H 2 NS(═O) 2 —, C 1-4 alkyl—NHS(═O) 2 —, and di(C 1-4 alkyl)NS(═O) 2 —.

2. The method of claim 1 , wherein:

represents a double bond;

Cy 1 is a five membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said five membered heteroaryl of Cy 1 is optionally substituted with 1, 2, or 3 groups independently selected from R 11 ;

R 1 is selected from H, F, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, OR a1 , C(═O)R b1 , C(═O)NR c1 , R d1 , and C(═O)OR a1 ;

R 2 is selected from H, F, and C 1-6 alkyl;

Cy 3 is selected from phenyl, C 3-7 cycloalkyl, a 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said phenyl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Cy 3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 ; additionally, wherein a ring-forming nitrogen atom of said 5-10 membered heteroaryl group or a ring-forming nitrogen atom of said 4-10 membered heterocycloalkyl group is optionally oxidized;

R 4 is H or C 1-6 alkyl;

R 5 is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, NR 15a R 15b , phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, 0 and S, wherein said C 1-6 alkyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R 5 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R 15 ;

R 6 is absent;

R 7 is selected from H, halo, CN, C 1-6 alkyl, C 1-6 alkoxy, phenyl, and 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said C 1-6 alkyl, phenyl, or 5-6 membered heteroaryl group, of R 7 are optionally substituted with 1, 2, or 3 groups independently selected from R 17 ;

R 8 is selected from H, halo, CN, OH, and C 1-6 alkyl;

R 11 is independently at each occurrence selected from H, C 1-3 alkyl, C 1-3 haloalkyl, halo, CN, OR a , NR c R d , SR b , and C(═O)NR c R d ;

R 13 is independently at each occurrence selected from H, halo, CN, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, OR a3 , SR a3 , C(═O)R b3 , C(═O)NR c3 R d3 , C(═O)OR a3 , OC(═O)R b3 , OC(═O)NR c3 R d3 , NR c3 R d3 , NR c3 C(═O)R b3 , NR c3 C(═O)NR c3 R d3 , NR c3 C(═O)OR a3 , S(═O)R b3 , S(═O)NR c3 R d3 , S(═O) 2 R b3, NR c3 S(═O) 2 R b3 and S(═O) 2 NR c3 R d3 , wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R 13 is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR a3 , SR a3 , C(═O)R b3 , C(═O)NR c3 R d3 , C(═O)OR a3 , OC(═O)R b3 , OC(═O)NR c3 R d3 , NR c3 R d3 , NR c3 C(═O)R b3 , NR c3 C(═O)NR c3 R d3 , NR c3 C(═O)OR a3 , S(═O)R b3 , S(═O)NR c3 R d3 , S(═O) 2 R b3 , NR c3 S(═O) 2 R b3 and S(═O) 2 NR c3 R d3 ;

R 15 is independently at each occurrence selected from H, halo, CN, OH, OR a5 , C(═O)R b5 , C(═O)NR c5 R d5 ; C(═O)OR a5 , NR c5 R d5 , and NR c5 C(═O)R b5 ;

R 15a and R 15b are independently selected from H and C 1-6 alkyl, wherein said C 1-6 alkyl of R 15a and R 15b is optionally substituted with 0, 1, 2, or 3 substituents selected from R 20 ;

R 17 is independently at each occurrence selected from halo, CN, OR a , NR c R d , SR b , and C(═O)NR c R d ;

R a , R c , and R d are independently at each occurrence selected from H and C 1-6 alkyl;

R b is at each occurrence C 1-6 alkyl;

R a1 , R b1 , R c1 and R d1 are independently at each occurrence selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 1-6 haloalkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl forming R a1 , R b1 , R c1 and R d1 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 20 ;

R a3 , R b3 , R c3 and R d3 are independently at each occurrence selected from H and C 1-6 alkyl, wherein said C 1-6 alkyl forming R a3 , R b3 , R c3 and R d3 is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, OR a4 , SR a4 , C(═O)R b4 , C(═O)NR c4 R d4 , C(═O)OR a4 , OC(═O)R b4 , OC(═O)NR c4 R d4 , NR c4 R d4 , NR c4 C(═O)R b4 , NR c4 C(═O)NR c4 R d4 , NR c4 C(═O)OR a4 , S(═O)R b4 , S(═O)NR c4 R d4 , S(═O) 2 R b4 , NR c4 S(═O) 2 R b4 and S(═O) 2 NR c4 R d4 ;

R a4 , R b4 , R c4 and R d4 are independently at each occurrence selected from H and C 1-6 alkyl, wherein said C 1-6 alkyl forming R a4 , R b4 , R c4 and R d4 is optinally substituted with 1, 2, or 3 substituents independently selected from R 20 ;

R a5 , R b5 , R c5 and R d5 are independently at each occurrence selected from H and C 1-6 alkyl, wherein said C 1-6 alkyl forming R a5 , R b5 , R c5 and R d5 is optionally substituted with 1, 2, or 3 substituents independently selected from R 20 ; and

R 20 is at each occurrence independently selected from H, halo, OH, CN, amino, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 alkyl—C(═O)—, C 1-4 alkyl—C(═O)O—, C 1-4 alkyl—OC(═O)—, HOC(═O)—, H 2 NC(═O)—, C 1-4 alkyl—NHC(═O)—, di(C 1-4 alkyl)NC(═O)—, C 1-4 alkyl—C(═O)NH—, C 1-4 alkyl—S(═O)—, H 2 NS(═O)—, C 1-4 alkyl—NHS(═O)—, di(C 1-4 alkyl)NS(═O)—, C 1-4 alkyl—S(═O) 2 —, C 1-4 alkyl—S(═O) 2 NH—, H 2 NS(═O) 2 —, C 1-4 alkyl—NHS(═O) 2 —, and di(C 1-4 alkyl)NS(═O) 2 —.

3. The method of claim 1 having Formula (Ia):

wherein:

represents a double bond;

Cy 1 is selected from isoxazolyl and pyrazolyl, wherein said isoxazolyl and pyrazolyl of Cy 1 is optionally substituted with 1 or 2 groups independently selected from R 1 is selected from H, methyl, —C(═O)OCH 2 CH 3 , —C(═O)N(H)CH 2 CH 3, —C(═O)N(H)CH 2 CH 2 OH, and —C(═O)N(CH 3 ) 2;

Cy 3 is selected from phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl and tetrahydrofuranyl, wherein said phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl and tetrahydrofuranyl of Cy 3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 ;

R 5 is H, methyl, —CH═CH 2, —N(H)CH 3 , —N(H)CH 2 CH 3 , —N(H)CH(CH 3 ) 2 , —N(CH 3 ) 2 , —N(H)CH 2 CH 2 OH, —N(H)CH(CH 3 )CH 2 OH, —N(H)CH 2 CH(OH)CH 3 , —N(H)C(CH 3 ) 2 CH 2 OH, —N(CH 3 )CH 2 CH 2 OH, morpholinyl, pyrrolidinyl, hydroxypyrrolidinyl, piperidinyl, hydroxypiperidinyl, azetidinyl, hydroxyazetidinyl, piperazinyl, butoxycarbonylpiperazinyl, and phenyl;

R 6 is absent;

R 7 is selected from H, F, Cl, Br, methyl, methoxy, ethoxy, CN, phenyl, and pyridinyl;

R 11 is independently at each occurrence selected from H, methyl, ethyl, chloro, and methoxy; and

R 13 is independently at each occurrence selected from H, F, CN, methoxy, —CF 3, —OCH 2 C(═O)OH, —OCH 2 C(═O)N(H)CH 2 CH 3, —OCH 2 C(═O)N(H)CH 2 CH 2 OH, and —OCH 2 C(═O)N(CH 3 ) 2 .

4. The method of claim 1 , wherein Cy 1 is isoxazolyl substituted with 1 or 2 groups independently selected from R 11 .

5. The method of claim 1 , wherein Cy 1 is pyrazolyl substituted with 1 or 2 groups independently selected from R 11 .

6. The method of claim 1 , wherein R l is selected from H, methyl, —CH 2 OH, —C(═O)OCH 2 CH 3, —C(═O)N(H)CH 2 CH 3, —C(═O)N(H)CH 3, —C(═O)NH 2, —C(═O)N(H)CH 2 CH 2 OH, and —C(═O)N(CH 3 ) 2 .

7. The method of claim 1 , wherein R 1 is selected from H, methyl, —C(═O)OCH 2 CH 3, —C(═O)N(H)CH 2 CH 3 , —C(═O)N(H)CH 2 CH 2 OH, and —C(═O)N(CH 3 ) 2 .

8. The method of claim 1 , wherein R 1 is H.

9. The method of claim 1 , wherein R 1 is methyl.

10. The method of claim 1 , wherein R 1 is —C(═O)OCH 2 CH 3 .

11. The method of claim 1 , wherein R 1 is C(═O)N(H)CH 2 CH 3 .

12. The method of any claim 1 , wherein R 1 is C(═O)N(H)CH 2 CH 2 OH.

13. The method of claim 1 , wherein R 1 is —C(═O)N(CH 3 ) 2 .

14. The method of claim 1 , wherein R 1 is —C(═O)N(H)CH 3 .

15. The method of claim 1 , wherein R 1 is —C(═O)NH 2 .

16. The method claim 1 , wherein R 1 is —CH 2 OH.

17. The method of claim 1 , wherein R 2 is H.

18. The method of claim 1 , wherein R 2 is methyl.

19. The method of claim 1 , wherein Cy 3 is selected from phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl, tetrahydrofuranyl, and piperinyl, wherein said phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl, tetrahydrofuranyl, and piperidinyl of Cy 3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

20. The method of claim 1 , wherein Cy 3 is selected from phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl and tetrahydrofuranyl, wherein said phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl and tetrahydrofuranyl of Cy 3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

21. The method of claim 1 , wherein Cy 3 is phenyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

22. The method of claim 1 , wherein Cy 3 is pyridinyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

23. The method of claim 1 , wherein Cy 3 is oxidopyridinyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

24. The method of claim 1 , wherein Cy 3 is thiazolyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

25. The method of claim 1 , wherein Cy 3 is cyclohexyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

26. The method of claim 1 , wherein Cy 3 is dihydrobenzofuranyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

27. The method of claim 1 , wherein Cy 3 is tetrahydrofuranyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

28. The method of claim 1 , wherein Cy 3 is piperidinyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R 13 .

29. The method of claim 1 , wherein R 4 is H, —C(═O)NH 2, —CH 2 NH 2 , —CH 2 N(H)C(═O)CH 3, —C(═O)N(H)CH 3 , —CH 2 CH 3, or —CH 3 .

30. The method of claim 1 , wherein R 4 is H.

31. The method of claim 1 , wherein R 5 is selected from H, C 1-4 alkyl, —CH═CH 2 , Nr 15a R 15b , —C(═O)NR 15a R 15b , phenyl, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C 1-4 alkyl, and 4-10 membered heterocycloalkyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R 15 .

32. The method of claim 1 , wherein R 5 is selected from H, C 1-4 alkyl, —CH═CH 2 , NR 15a R 15b , —C(═O)NR 15a R 15b , phenyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,5-dihydro-1H-pyrrolyl, 1,4-diazepanyl, morpholinyl, and octahydropyrrolo[1,2-a]pyrazinyl, wherein said C 1-4 alkyl, phenyl, azetidinyl, pyrolidinyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,5-dihydro -1H-pyrrolyl, 1,4-diazepanyl, morpholinyl, and octahydropyrrolo[1,2-a]pyrazinyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R 15 .

33. The method of claim 1 , wherein R 5 is H, methyl, —CH═CH 2 , —N(H)CH 3, —N(H)CH 2 CH 3, —N(H)CH(CH 3 ) 2, —N(CH 3 ) 2, —N(H)CH 2 CH 2 OH, —N(H)CH(CH 3 )CH 2 OH, —N(H)CH 2 CH(OH)CH 3, —N(H)C(CH 3 ) 2 CH 2 OH, —N(CH 3 )CH 2 CH 2 OH, morpholinyl, pyrrolidinyl, hydroxypyrrolidinyl, piperidinyl, hydroxypiperidinyl, azetidinyl, hydroxyazetidinyl, piperazinyl, butoxycarbonylpiperazinyl or phenyl.

34. The method of claim 1 , wherein R 5 is selected from a 4-6 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said 4-6 membered heterocycloalkyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R 15 .

35. The method of claim 1 , wherein R 5 is pyrrolidinyl, piperidinyl, azetidinyl, or piperazinyl, wherein said pyrrolidinyl, piperidinyl, azetidinyl, or piperazinyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R 15 .

36. The method of claim 1 , wherein R 5 is pyrrolidinyl, wherein said pyrrolidinyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R 15 .

37. The method of claim 1 , wherein R 5 is piperidinyl, wherein said piperidinyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R15.

38. The method of claim 1 , wherein R 5 is azetidinyl, wherein said azetidinyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R 15 .

39. The method of claim 1 , wherein R 5 is piperazinyl, wherein said piperazinyl of R 5 is optionally substituted by 1 or 2 groups independently selected from R 15 .

40. The method of claim 1 , wherein R 15 is independently at each occurrence selected from C 1-6 alkyl, CN, OR a5 , C(═O)R b5 , C(═O)NR c5 R d5 , C(═O)OR a5 , NR c5 R d5 , NR c5 C(═O)R b5 , NR c5 C(═O)NR c5 R d5 , NR c5 C(═O)OR a5 , S(═O)R b5 , NR c5 S(═O) 2 R b5 , and S(═O) 2 NR c5 R d5 , wherein said C 1-6 alkyl, is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR a5 , SR a5 , C(═O)R b5 , C(═O)NR c5 R d5 , C(═O)OR a5 , OC(═O)R b5 , OC(═O)NR c5 R d5 , NR c5 R d5 , NR c5 C(═O)R b5 , NR c5 C(═O)NR c5 R d5 , NR c5 C(═O)OR a5 , S(═O)R b5 , S(═O)NR c5 R d5 , S(═O) 2 R b5 , NR c5 S(═O) 2 R b5 , S(═O) 2 NR c5 R d5 , 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl, and C 3-7 cycloalkyl.

41. The method of claim 1 , wherein R 7 is selected from H, halo, CN, NR c R d , C 1-6 alkyl, C 2-6 alkenyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 5-6 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C 1-6 alkyl, C 2-6 alkenyl, 5-6 membered heteroaryl group, and 5-6 membered heterocycloalkyl group of R 7 are optionally substituted with 1, 2, or 3 groups independently selected from R 17 .

42. The method of claim 1 , wherein R 7 is selected from H, F, Cl, Br, CN, NR c R d , C 1-4 alkyl, C 2-4 alkenyl, pyrazolyl, pyridinyl, pyrimidinyl, and 1,2,3,6-tetrahydropyridinyl, wherein said C 1-4 alkyl, C 2-4 alkenyl, pyrazolyl, pyridinyl, pyrmimidinyl, and 1,2,3,6-tetrahydropyridinyl of R 7 are optionally substituted with 1, 2, or 3 groups independently selected from R 17 .

43. The method of claim 1 , wherein R 7 is selected from H, halo, C 1-4 alkyl, and CN.

44. The method of claim 1 , wherein R 7 is selected from H, Br, methyl, and CN.

45. The method of claim 1 , wherein R 7 is H.

46. The method of claim 1 , wherein R 7 is Br.

47. The method of claim 1 , wherein R 7 is methyl.

48. The method of claim 1 , wherein R 7 is CN.

49. The method of claim 1 , wherein R 8 is selected from H, halo, C 1-4 alkyl, and CN.

50. The method of claim 1 , wherein R 8 is H.

51. The method of claim 1 , wherein the compound of Formula (I) is a compound having Formula (IIb):

52. The method of claim 1 , wherein the compound of Formula (I) is a compound having Formula (IIIb):

53. The method of claim 1 , wherein the compound of Formula (I) is a compound having Formula (IVb):

54. The method of claim 1 , wherein the compound of Formula (I) is a compound selected from:

7-(3,5-dimethylisoxazol-4-yl)-2-methyl-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

7-(3,5-Dimethylisoxazol-4-yl)-N-isopropyl-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

7-(3,5-Dimethylisoxazol-4-yl)-N-methyl-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

7-(3,5-Dimethylisoxazol-4-yl)-N-ethyl-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

7-(3,5-Dimethylisoxazol-4-yl)-N,N-dimethyl-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

2-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino}ethanol;

2-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino}propan-1-ol;

1-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino}propan-2-ol;

2-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino}-2-methylpropan-1-ol;

2-[[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]methyl)amino]ethanol;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

7-(3,5-dimethylisoxazol-4-yl)-4-phenyl-2-piperazin-1-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

7-(3,5-dimethylisoxazol-4-yl)-2,4-diphenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

7-(3,5-Dimethylisoxazol-4-yl)-2-morpholin-4-yl-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-2-pyrrolidin-1-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-2-piperidin-1-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-ol;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-3-ol;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-ol; and

4-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazine-1-carboxylate;

or a pharmaceutically acceptable salt thereof.

55. The method of claim 1 , wherein the compound of Formula (I) is a compound selected from:

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-vinyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(1R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]ethane-1,2-diol;

1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]ethanol;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-N,N-dimethyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxamide;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

tert-Butyl (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxylate;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-(morpholin-4-ylcarbonyl)-4-pyridin-2-yl -4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-N-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxamide;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxamide;

tert-Butyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3,6-dihydropyridine-1(2H)-carboxylate;

tert-Butyl 3-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-2,5-dihydro-1H-pyrrole-1-carboxylate;

tert-Butyl 5-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3,6-dihydropyridine-1(2H)-carboxylate;

tert-Butyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-1-carboxylate;

tert-Butyl 3-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidine-1-carboxylate;

tert-Butyl 3-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-1-carboxylate;

(4S)-2-(1-Acetylpiperidin-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-(1,2,3,6-tetrahydropyridin-4-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(2,5-dihydro-1H-pyrrol-3-yl)-'7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-pyrrolidin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-(1,2,5,6-tetrahydropyridin-3-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-piperidin-3-yl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-Acetylpiperidin-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-[1-(cyclopropylcarbonyl)piperidin-4-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[1-(methylsulfonyl)piperidin-4-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetylpyrrolidin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-[1-(cyclopropylcarbonyl)pyrrolidin-3-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[1-(methylsulfonyl)pyrrolidin-3-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetyl-1,2,5,6-tetrahydropyridin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetylpiperidin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-[1-(cyclopropylcarbonyl)piperidin-3-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[1-(methylsulfonyl)piperidin-3-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(3R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-isopropylpyrrolidine-3-carboxamide;

1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3-methylpyrrolidin-3-ol;

4-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-1,4-diazepane-1-sulfonamide;

(4S)-2-(4-Acetyl-1,4-diazepan-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-[4-(methylsulfonyl)-1,4-diazepan-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-piperazin-1-yl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

2-{4-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazin-1-yl}-N,N-dimethylacetamide;

2-Cyano-N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N-methylacetamide;

N-{(3R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}morpholine-4-carboxamide;

7-(3,5-Dimethylisoxazol-4-yl)-2-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

Methyl {(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}carbamate;

7-(3,5-Dimethylisoxazol-4-yl)-9-fluoro-N,N-dimethyl-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

1-[7-(3,5-Dimethylisoxazol-4-yl)-9-fluoro-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

7-(3,5-Dimethylisoxazol-4-yl)-N-ethyl-9-fluoro-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

(3R)-1-[7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-ol;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-morpholin-4-yl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-pyrrolidin-1-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-methylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-azetidin-1-yl-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-ol;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-1-methylpiperazin-2-one;

ethyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazine-1-carboxylate;

(3R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

(3S)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-ol;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]piperidin-3-ol;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]piperidin-3-ol;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N,N-dimethylpiperidin-4-amine;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazin-2-one;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(methylsulfonyl)piperazin-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-isopropylpiperazin-1-yl)-4-pyridin-2-yl -4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-4-carbonitrile;

{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}methanol;

2-{4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]piperazin-1-yl}ethanol;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-phenylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazine;

(4S)-2-(4-benzylpiperazin-1-yl)-'7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazine;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]-N,N-dimethylpyrrolidin-3-amine;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]-N,N-dimethylpyrrolidin-3-amine;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpyrrolidin-3-amine;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpyrrolidin-3-amine;

tert-butyl {(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}carbamate;

tert-butyl {(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}carbamate;

(4S)-2[4-(cyclopropylmethyl)piperazin-1-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(2-methoxyethyl)piperazin-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

2-[[7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl](methyl)amino]ethanol;

7-(3,5-dimethylisoxazol-4-yl)-N-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

7-(3,5-dimethylisoxazol-4-yl)-N,N-dimethyl-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1, 4]benzoxazin-2-amine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-4-carboxamide;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpiperidine-4-carboxamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}acetamide;

2-{4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]piperazin-1-yl}acetamide;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-ethylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin -2(1H)-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin -2(1H)-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-4-methylpiperidin-4-ol;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3-methylpiperazin-2-one;

tert-butyl {1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}carbamate;

tert-butyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-1,4-diazepane-1-carboxylate;

2-{[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino }ethanol;

tert-butyl (2-{[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino }ethyl)carbamate;

N-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]ethane-1,2-diamine;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}acetamide;

N-{(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}acetamide;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-amine;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-amine;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2,2,2-trifluoroacetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2-methoxyacetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}cyclopropanecarboxamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}methanesulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}propanamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2-methylpropanamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}cyclobutanecarboxamide;

2-cyano-N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}acetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl }tetrahydro-2H-pyran-4-carboxamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}ethanesulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}propane-1-sulfonamide;

N′-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N,N-dimethylurea;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}propane-2-sulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}cyclopropanesulfonamide;

methyl{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}methylcarbamate;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N -methylmethanesulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2-methoxy-N -methylacetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N-methylacetamide;

(4S)-2-(4-acetylpiperazin-1-yl)-'7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-propionylpiperazin-1-yl)-4-pyridin-2-yl -4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(ethylsulfonyl)piperazin-1-yl]-4-pyridin -2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin -1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazine-1-sulfonamide;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-amine;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}acetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}propanamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}-2-methylpropanamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}-2-methoxyacetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}cyclopropanecarboxamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}cyclobutanecarboxamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}methanesulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}ethanesulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo [1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}propane-2-sulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}methanesulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}-2-methoxyacetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}-2,2,2-trifluoroacetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}propanamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}propanamide;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-propionyl-1,4-diazepan-1-yl)-4-pyridin -2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(ethylsulfonyl)-1,4-diazepan-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpyrrolidine-3-carboxamide;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-ethylpyrrolidine-3-carboxamide; and

(3R)-N-cyclopropyl-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidine-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

56. The method of claim 1 , wherein the cancer is leukemia.

57. The method of claim 1 , wherein the compound of Formula (I) is a compound having the structure:

or a pharmaceutically acceptable salt thereof.

58. The method of claim 1 , wherein the compound of Formula (I) is (4S)-2-(4-acetylpiperazin-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine, or a pharmaceutically acceptable salt thereof.

59. The method of claim 56 , wherein the leukemia is acute myelogenous leukemia.

60. The method of claim 56 , wherein the leukemia is acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aggressive NK-cell leukemia, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, or mast cell leukemia.

61. The method of claim 1 , wherein the cancer is lymphoma.

62. The method of claim 61 , wherein the lymphoma is adult T-cell lymphoma, AIDS-related lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, cutaneous T-cell lymphoma, enteropathy-associated T-cell lymphoma, follicular lymphoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, MALT lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, precursor T -lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, splenic marginal zone lymphoma, or T-cell lymphoma.

63. The method of claim 61 , wherein the lymphoma is diffuse large B-cell lymphoma.

64. The method of claim 1 , wherein the cancer is multiple myeloma.

65. The method of claim 1 , wherein the cancer is brain cancer.

66. The method of claim 65 , wherein the brain cancer is glioblastoma multiforme, glioma, visual pathway glioma, gliomatosis cerebri, or oligodendroglioma.

67. The method of claim 1 , wherein the cancer is neuroblastoma.

68. The method of claim 1 , wherein the cancer is carcinoma.

69. The method of claim 68 , wherein the carcinoma is acinic cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, adenosquamous carcinoma, adrenocortical carcinoma, basal cell carcinoma, carcinoma in situ, carcinosarcoma, choriocarcinoma, embryonal carcinoma, gestational choriocarcinoma, invasive lobular carcinoma, lethal midline carcinoma, medullary carcinoma of the breast, metastatic urothelial carcinoma, nasopharyngeal carcinoma, renal cell carcinoma, renal medullary carcinoma, signet ring cell carcinoma, small cell carcinoma, squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma, or verrucous carcinoma.

70. The method of claim 1 , wherein the cancer is skin cancer.

71. The method of claim 70 , wherein the skin cancer is melanoma, acral lentiginous melanoma, nodular melanoma, or uveal melanoma.

72. The method of claim 1 , wherein the cancer is lung cancer.

73. The method of claim 1 , wherein the cancer is prostate cancer.